Vulva Cancer

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Vulva Cancer

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer 12 14
Vulva Carcinoma 12 52 14
Carcinoma of Vulva 12 69
Vulvar Neoplasms 42 69
Vulvar Cancer 50 41
Malignant Neoplasm of Vulva, Unspecified 12
Malignant Neoplasm of Vulva Unspecified 12
Malignant Neoplasm of Vulva, Nos 12
Malignant Neoplasm of Vulva 69
Malignant Tumor of Vulva 12
Malignant Vulvar Tumor 12
Neoplasm of Vulva 12
Vulvar Carcinoma 12
Vulval Neoplasm 12
Vulvar Neoplasm 12
Vulval Cancer 12
Vulvar Tumor 12
Ca Vulva 12


Summaries for Vulva Cancer

MedlinePlus : 41 vulvar cancer is a rare type of cancer. it forms in a woman's external genitals, called the vulva. the cancer usually grows slowly over several years. first, precancerous cells grow on vulvar skin. this is called vulvar intraepithelial neoplasia (vin), or dysplasia. not all vin cases turn into cancer, but it is best to treat it early. often, vulvar cancer doesn't cause symptoms at first. however, see your doctor for testing if you notice a lump in the vulva vulvar itching or tenderness bleeding that is not your period changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer you are at greater risk if you've had a human papillomavirus (hpv) infection or have a history of genital warts. your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. treatment varies, depending on your overall health and how advanced the cancer is. it might include surgery, radiation therapy, chemotherapy, or biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute

MalaCards based summary : Vulva Cancer, also known as vulva carcinoma, is related to vulva squamous cell carcinoma and bartholin's gland benign neoplasm, and has symptoms including pruritus vulvae and pelvic pain. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Glioblastoma Multiforme and Photodynamic therapy-induced AP-1 survival signaling.. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and skin.

Disease Ontology : 12 A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

NIH Rare Diseases : 50 vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina.  symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding.  though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer.  treatment may include laser therapy, surgery, chemotherapy, or radiation therapy. last updated: 7/27/2012

Wikipedia : 72 Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Related Diseases for Vulva Cancer

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
id Related Disease Score Top Affiliating Genes
1 vulva squamous cell carcinoma 29.5 CDKN2A KRT7 LINC01191 PIP UPK3A
2 bartholin's gland benign neoplasm 10.9
3 vulva adenocarcinoma 10.9
4 vulvar disease 10.9
5 vaginal disease 10.9
6 pediatric infratentorial ependymoma 10.8 EGFR TP53
7 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.8 CDKN2A EGFR
8 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
9 malignant giant cell tumor of soft parts 10.8 CDKN2A EGFR
10 split hand split foot nystagmus 10.8 CDKN2A TP53
11 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.8 EGFR TP53
12 leiomyoma cutis 10.8 CDKN2A TP53
13 anal squamous cell carcinoma 10.8 CDKN2A TP53
14 childhood infratentorial neoplasm 10.7 EGFR TP53
15 rectum squamous cell carcinoma 10.7 CDKN2A TP53
16 breast myoepitheliosis 10.7 CDKN2A TP53
17 duodenum cancer 10.7 CDKN2A TP53
18 penis paget's disease 10.7 CDKN2A TP53
19 phalanx chondroma 10.7 CDKN2A TP53
20 olfactory neural tumor 10.7 CDKN2A TP53
21 rete testis neoplasm 10.7 CDKN2A EGFR
22 orbital lymphoma 10.7 CDKN2A TP53
23 non-suppurative otitis media 10.7 CDKN2A TP53
24 congenital mesoblastic nephroma 10.7 EGFR TP53
25 mediastinum seminoma 10.7 TP53 UPK3A
26 neurofibroma of the heart 10.7 KRT13 TP53
27 pancreatic agenesis 10.7 CDKN2A TP53
28 rete testis adenoma 10.7 TP53 UPK3A
29 extragonadal nonseminomatous germ cell tumor 10.7 EGFR TP53
30 rhinosporidiosis 10.6 KRT13 UPK3A
31 secondary pulmonary hemosiderosis 10.6 CDKN2A TP53
32 villous adenocarcinoma 10.6 CDKN2A TP53
33 lymphopenia 10.6 EGFR TP53
34 sparse hair ptosis mental retardation 10.6 EGFR TP53
35 pleuropneumonia 10.6 CDKN2A LINC01191
36 spastic ataxia 3 10.5 CDKN2A TP53
37 multiple carboxylase deficiency 10.5 CDKN2A EGFR TP53
38 cecum adenocarcinoma 10.5 CDKN2A EGFR TP53
39 pediatric osteosarcoma 10.5 CDKN2A TP53
40 myxedema 10.5 CDKN2A EGFR TP53
41 benign dermal neurilemmoma 10.5 CDKN2A SERPINB3
42 anaerobic pneumonia 10.5 CDKN2A EGFR TP53
43 integumentary system cancer 10.5 CDKN2A EGFR TP53
44 cystic lymphangioma 10.5 CDKN2A EGFR TP53
45 pancreatic somatostatinoma 10.5 CDKN2A EGFR TP53
46 bladder squamous cell carcinoma 10.5 CDKN2A TP53
47 paroxysmal nocturnal hemoglobinuria 10.5 CDKN2A EGFR TP53
48 nasopharyngeal carcinoma 10.5 CDKN2A EGFR TP53
49 bladder urachal squamous cell carcinoma 10.5 CDKN2A EGFR TP53
50 spinal cord glioma 10.5 CDKN2A EGFR TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis Clitoris Cancer
Hypertension, Essential Localized Scleroderma
Vaginal Cancer Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:

Diseases related to Vulva Cancer

Symptoms & Phenotypes for Vulva Cancer

UMLS symptoms related to Vulva Cancer:

pruritus vulvae, pelvic pain

Drugs & Therapeutics for Vulva Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
Menthol Approved Phase 3 2216-51-5 16666
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
6 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
7 Liver Extracts Phase 3,Phase 2,Phase 1
8 Coagulants Phase 3
9 Fibrin Tissue Adhesive Phase 3
10 Hemostatics Phase 3
11 Vaccines Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Hormonal Phase 3
13 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1
14 Adjuvants, Anesthesia Phase 3
15 Analgesics Phase 3,Phase 2
16 Analgesics, Opioid Phase 3
17 Anesthetics Phase 3
18 Anesthetics, General Phase 3
19 Anesthetics, Intravenous Phase 3
20 Central Nervous System Depressants Phase 3
21 Narcotics Phase 3
22 Peripheral Nervous System Agents Phase 3,Phase 2
23 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
24 Cola Nutraceutical Phase 3,Phase 2,Phase 1
25 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3
Indinavir Approved Phase 2 150378-17-9 5362440
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
Bevacizumab Approved, Investigational Phase 2 216974-75-3
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
Daratumumab Approved Phase 1, Phase 2 945721-28-8
nivolumab Approved Phase 1, Phase 2 946414-94-4
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
Pembrolizumab Approved Phase 2 1374853-91-4
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
Clobetasol Investigational Phase 2 25122-46-7, 25122-41-2 32798 5311051
42 Fondaparinux Investigational Phase 2 104993-28-4
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
44 Anti-HIV Agents Phase 2
45 Anti-Infective Agents Phase 2,Phase 1
46 Anti-Retroviral Agents Phase 2
47 Antiviral Agents Phase 2,Phase 1
48 Cytochrome P-450 CYP3A Inhibitors Phase 2
49 Cytochrome P-450 Enzyme Inhibitors Phase 2
50 HIV Protease Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 126)

id Name Status NCT ID Phase Drugs
1 Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Completed NCT00003325 Phase 3
2 Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Completed NCT00898352 Phase 3
3 Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed NCT00028951 Phase 3 fibrin sealant
4 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Completed NCT00224744 Phase 3
5 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
6 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
7 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
8 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
9 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
10 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
11 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
14 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Recruiting NCT03158220 Phase 3
15 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
16 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
17 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Not yet recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
18 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva Terminated NCT00006096 Phase 3 cisplatin
19 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
20 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
21 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
22 Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva Completed NCT00014599 Phase 2 paclitaxel
23 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Completed NCT00068406 Phase 2 cisplatin
24 The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence Completed NCT01986725 Phase 2
25 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar Completed NCT00476476 Phase 2 Erlotinib
26 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
27 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
28 Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Completed NCT00393263 Phase 2 pimecrolimus and clobetasol;clobetasol 0.05% cream
29 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
30 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
31 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
32 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
33 Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
34 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
35 VGX-3100 Followed by Electroporation Alone or in Combination With Imiquimod for the Treatment of Human Papilloma Virus HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva Recruiting NCT03180684 Phase 2 Imiquimod 5% cream
36 Image-Guided Gynecologic Brachytherapy Recruiting NCT02993900 Phase 2
37 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Recruiting NCT01764802 Phase 2
38 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
39 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
40 Biobehavioral Intervention in Gynecologic Oncology Patients Recruiting NCT02454036 Phase 2
41 Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Active, not recruiting NCT01406769 Phase 2
42 Image-Guided Gynecologic Brachytherapy Active, not recruiting NCT01399658 Phase 2
43 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Active, not recruiting NCT00754078 Phase 2
44 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Not yet recruiting NCT03220009 Phase 2
45 Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Terminated NCT00003525 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
47 Sentinel Node in Ovarian Cancer Unknown status NCT01734746 Phase 1
48 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
49 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
50 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Genetic Tests for Vulva Cancer

Anatomical Context for Vulva Cancer

MalaCards organs/tissues related to Vulva Cancer:

Lymph Node, Testes, Skin, Cervix, Liver, Brain, Prostate

Publications for Vulva Cancer

Articles related to Vulva Cancer:

(show all 14)
id Title Authors Year
Vulva cancer in Ghana - Review of a hospital based data. ( 28409179 )
Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? ( 28034465 )
The Added Value of Pathology Review in Vulva Cancer: Results From a Population-based Cohort Study. ( 27513080 )
Could Sentinel Node Mapping of the Groin Cause Extranodal Metastasis in Vulva Cancer? ( 25412581 )
Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )
Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )
The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )
Assessment of promising protein markers for vulva cancer. ( 19509584 )
An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )
Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )
Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )
Inguinal node status by ultrasound in vulva cancer. ( 10739696 )
Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )
T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )

Variations for Vulva Cancer

Cosmic variations for Vulva Cancer:

id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM498 HRAS skin,genital,carcinoma,NS c.182A>T p.Q61L 7
2 COSM10662 TP53 skin,lip,carcinoma,NS c.743G>A p.R248Q 6
3 COSM12296 TP53 skin,lip,carcinoma,NS c.292C>T p.P98S 6
4 COSM17598 PTCH1 skin,lip,carcinoma,NS c.550C>T p.Q184* 6
5 COSM26363 PTCH1 skin,lip,carcinoma,NS c.2446C>T p.Q816* 6

Expression for Vulva Cancer

Search GEO for disease gene expression data for Vulva Cancer.

Pathways for Vulva Cancer

Pathways related to Vulva Cancer according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.38 CDKN2A EGFR TP53
2 10.84 CDKN2A EGFR TP53
3 10.79 CDKN2A EGFR TP53 UPK3A
4 10.66 CDKN2A TP53
Show member pathways
10.6 CDKN2A TP53

GO Terms for Vulva Cancer

Cellular components related to Vulva Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.23 GP5 KRT13 KRT7 PIP PLXDC2 SERPINB3

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.32 TP53

Sources for Vulva Cancer

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....